Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Bristol-Myers Squibb is conducting a Phase 3 study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-1)’. The study aims to assess the effectiveness and safety of deucravacitinib compared to a placebo in individuals with moderate to severe SLE, a significant autoimmune disease affecting multiple organs.
Intervention/Treatment: The study tests deucravacitinib, an experimental drug, against a placebo. Deucravacitinib is intended to manage symptoms and improve the quality of life for those with active SLE.
Study Design: This interventional study is randomized with a parallel assignment. It employs quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the group assignments. The primary goal is treatment-focused.
Study Timeline: The study began on January 12, 2023, and is currently recruiting participants. The last update was submitted on August 7, 2025, indicating ongoing progress and data collection.
Market Implications: The successful development of deucravacitinib could positively impact Bristol-Myers Squibb’s stock performance by expanding its portfolio in the autoimmune disease market. Investors should watch for updates, as positive results could enhance market competitiveness against other pharmaceutical companies in the SLE treatment space.
The study is ongoing, with further details available on the ClinicalTrials portal.